Revelation Biosciences
REVB
11 hedge funds and large institutions have $600K invested in Revelation Biosciences in 2026 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 4 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
211% more capital inflows, than outflows
Capital inflows: $541K | Capital outflows: $174K
5.16% more ownership
Funds ownership: 8.27% → 13.43% (+5.2%)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
8% less funds holding
Funds holding: 12 → 11 (-1)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
+$415K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$67.1K |
| 3 |
XTX Topco
George Town,
Cayman Islands
|
+$16.5K |
| 4 |
Tower Research Capital (TRC)
New York
|
+$7.88K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$7.61K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$101K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$43.8K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$17.5K |
| 4 |
HRT Financial
New York
|
-$12K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$38 |
REVB Hedge Fund Activity: Q1 2026 in Review
11 of the 8,232 institutional investors tracked by Wall St. Rank reported a position in Revelation Biosciences (REVB) for Q1 2026, worth a combined $600K — down 39% from $984K a quarter earlier.
Fund positioning in REVB was balanced in Q1 2026: 4 funds opened new positions, 4 closed out, 5 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, adding an estimated $415K. The largest seller was Sabby Management, cutting an estimated $101K.
- 11 institutional investors held Revelation Biosciences (REVB) as of Q1 2026, down from 12 in Q4 2025.
- Funds reported $600K of Revelation Biosciences stock for Q1 2026, down 39% quarter-over-quarter.
- 4 funds opened new Revelation Biosciences positions in Q1 2026 and 4 closed out, a net change of 0 holders.
- The largest Revelation Biosciences buyer in Q1 2026 was Armistice Capital, an estimated $415K added.
- The largest Revelation Biosciences seller in Q1 2026 was Sabby Management, an estimated $101K sold.
Based on aggregated 13F filings for Q1 2026.